Accessibility Menu
Tenax Therapeutics logo

Tenax Therapeutics(NASDAQ) TENX

Market Cap$385.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1993)-100%
5 Year-99%
1 Year+168%
1 Month+20%
$16.25
+11.84%
+1.72Today
Tenax Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 16.192026-07-27
Tenax Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.25%USD 15.682026-07-20
1 month+20.46%USD 13.442026-06-26
3 month+10.89%USD 14.602026-04-28
Year to date+32.81%USD 12.192025-12-31
1 year+167.6%USD 6.052025-07-25
3 year-36.76%USD 25.602023-07-28
5 year-99.43%USD 2,848.002021-07-28
Since inception-100%USD 27,543,186.181993-03-16

Tenax Therapeutics Financials at a Glance

Market Cap

$385.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$57.91M

EPS (TTM)

-$1.40

P/E Ratio

-10.39

Dividend

$0.00

Beta (Volatility)

0.41 (Low)

Price

$16.25

Volume

38,435

Open

$14.92

Previous Close

$16.25

Daily Range

$14.92 - $16.25

52-Week Range

$5.78 - $19.40

Estimated Earnings Date

Aug 12, 2026

TENX News

Foolcom-Featured.png

Tenax Posts Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 13, 2025

Oxygen Biotherapeutics Expands TBI Trials to India, Seeks Partner

MedCity NewsJun 8, 2011

TENX: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tenax Therapeutics

Tenax Therapeutics develops medicines for people with serious heart and lung diseases. It creates new ways to use existing drugs for high blood pressure in the lungs. These products help patients breathe better and stay more active.

The Treatment Pipeline

  • TNX-103: Oral medicine in late-stage testing for high blood pressure caused by heart failure; currently in two Phase 3 trials.
  • TNX-201: Specialized version of imatinib for a rare lung artery disease; holds orphan drug status for potential market exclusivity.
  • TNX-102: Version of levosimendan delivered under the skin; intended for treating various cardiovascular and pulmonary conditions.

Strategic Moves and Partners

  • Acquired PHPrecisionMed Inc. in January 2021 to add a potential lung disease treatment to its portfolio.
  • Expanded a global license with Orion Corporation in February 2024 for the rights to oral levosimendan.
  • Updated a manufacturing deal with Orion Corporation in September 2025 to secure essential medicine ingredients.
  • Initiated the global LEVEL-2 clinical trial in December 2025 to test its primary drug candidate.

Focused Development Model

The company focuses on drugs already safely used in millions of patients for over two decades. It operates with a lean team of 14 employees and relies on outside partners to run global clinical trials.

Financial Performance

  • Net income was negative $15.5 million in Q4 2025, worsening by 148% from negative $6.3 million in Q4 2024.
  • Operating cash flow hit negative $13.4 million in Q4 2025, a 280% deepened loss compared to the previous year.
  • Operating income reached negative $16.4 million in Q4 2025, worsening by 125.5% year-over-year.
  • Cash and cash equivalents totaled $97.6 million as of December 31, 2025.

Bottom Line

Tenax has evolved into a late-stage developer focused on reusing established drugs for new heart and lung treatments. Its strategy relies on strategic partnerships and outsourced manufacturing to manage costs while pursuing regulatory approvals.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Christopher T. Giordano

Website

www.tenaxthera.com

Headquarters

Chapel Hill, NC 27560, US

TENX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-56.32%

Return on Capital

-58.09%

Return on Assets

-47.01%

Earnings Yield

-9.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$385.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

26.53M

Volume

38.44K

Avg. Volume

1.04M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$61.62M

EBITDA

-$57.91M

Operating Cash Flow

-$38.14M

Capital Expenditure

$0.00

Free Cash Flow

-$38.14M

Cash & ST Invst.

$118.76M

Total Debt

$0.00

Tenax Therapeutics Performance Analysis

Tenax Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tenax Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Tenax Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -600.72-76.2%
20232023-12-31USD -31.04-94.8%
20242024-12-31USD -1.15-96.3%
20252025-12-31USD -1.3416.4%
Tenax Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-303.6%
Q32025-09-30-48.1%
Q42025-12-312.5%
Q12026-03-3110.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$385.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$24.09M

N/A

Employees

16

N/A

Net Income

-$15.72M

-51.0%

EBITDA

-$15.72M

-51.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$118.76M

+6.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-47.01%

N/A

Return on Invested Capital

-53.73%

N/A

Free Cash Flow

-$9.31M

-33.6%

Operating Cash Flow

-$9.31M

-33.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QTTBQ32 Bio Inc.
$15.21+0.40%
ANTXAN2 Therapeutics, Inc.
$4.93+0.20%
VRCAVerrica Pharmaceuticals Inc.
$5.35+6.57%
BOLDBoundless Bio, Inc.
$2.48-3.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$63.40-0.01%
SPCXSpace Exploration Technologies
$113.50-0.01%

Questions About TENX

What is the current price of Tenax Therapeutics?

Tenax Therapeutics is trading at $16.25 per share.

What is the 52-week range for Tenax Therapeutics?

Over the past 52 weeks, Tenax Therapeutics has traded between $5.78 and $19.40.

How much debt does Tenax Therapeutics have?

As of the most recent reporting period, Tenax Therapeutics reported total debt of $0.00.

How much cash does Tenax Therapeutics have on hand?

Tenax Therapeutics reported $118.76M in cash and cash equivalents in its most recent financial results.

What is Tenax Therapeutics’s dividend yield?

Tenax Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services